Apricus Biosciences, Inc.
) announced the launch of its sole approved product, Vitaros in
Germany. Vitaros is an on-demand topical cream formulation for
treating patients suffering from erectile dysfunction ED).
In Jun 2013, Vitaros had received European approval through the
European Decentralized Procedure (DCP). Subsequently, the company
gained national phase approval for Vitaros in France, Germany,
Ireland, Italy, the Netherlands, Sweden, the UK and Belgium.
The launch of Vitaros in Germany (one of the largest ED markets
in the EU) marks the company's third launch in the last three
months. Apricus launched Vitaros in the UK (commercialized by
Takeda) in June and in Sweden (commercialized by Sandoz) earlier
Vitaros will be commercialized in Germany by Hexal AG, an
affiliate of Sandoz, a Novartis (
Apricus has a licensing deal with Sandoz for the commercialization
of Vitaros in Germany, Austria, Belgium, Denmark, Finland, Iceland,
Luxemburg, the Netherlands, Norway, Sweden and Switzerland.
Apricus has partnerships with several companies for the
commercialization of Vitaros. Vitaros is currently licensed to
companies like Abbott Laboratories (
), Sandoz, Recordati, Bracco and Majorelle among others. The
company expects to earn milestone revenues of more than $200
million and tiered double digit royalties under its partnership
Apricus expects additional product launches by partners throughout
Meanwhile, Apricus is developing a second-generation Vitaros with a
stabilized dosage formulation due to which the drug can be stored
at room temperature. If successfully developed, this
second-generation Vitaros is expected to be available in 2016.
Apricus carries a Zacks Rank #3 (Hold). A better-ranked stock in
the pharmaceutical sector is Endo International plc (
), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ENDO INTL PLC (ENDP): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
ABBOTT LABS (ABT): Free Stock Analysis Report
APPRICUS BIOSCI (APRI): Free Stock Analysis
To read this article on Zacks.com click here.